Latest News

Ocrelizumab Subcut Receives Medsafe Registration as Pressure Mounts to Fund Wider Range of MS Treatment Options

April 24, 2025 | Advocacy, Life with MS, News, Treatments

Photo by Kristine Wook, Unsplash. Medsafe have approved the registration of Ocrevus ® Subcutaneous (SC) (ocrelizumab and hyaluronidase) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS). The announcement on […]


MSNZ President Calls for Pharmac to Fund 4 New Drugs on TVNZ Breakfast

March 27, 2025 | Advocacy, Event, Media, News, Treatments

Watch MSNZ President, Neil Woodhams, on TVNZ Breakfast today where he calls for Pharmac to fund 4 new drugs for MS treatment. Neil Woodhams attended this interview ahead of us appearing at Parliament later this morning, with the Bangers to Bluff […]


Press Release: Pharmac Funding Stalemate for “Life-Changing” Multiple Sclerosis Drugs

March 27, 2025 | Advocacy, Media, News, Press Release, Treatments

There are calls for Pharmac to “quit stalling” and fund four affordable treatments to significantly improve quality of life for patients with Multiple Sclerosis (MS) in New Zealand – treatments which would also significantly reduce demand on New Zealand’s stretched […]


Our Submission to Disability Support Services Consultation

March 25, 2025 | Advocacy, Life with MS, News, Support

Following our two open platform sessions on 12th March where we gathered your comments, insights and feedback into the review of Disability Support Services (DSS), we are pleased to share with you our submission and recommendations. During our sessions, we […]


MS Voice Newsletter – February 2025

February 27, 2025 | Advocacy, Carer, Carers, Event, Life with MS, MS Voice, News, Newsletter

Welcome to the February edition of MS Voice—your trusted source for the latest news, updates, and real-life stories from Multiple Sclerosis New Zealand and the MS community. This year promises to be a dynamic one as we continue our commitment to […]